However, a potentially important finding of this study is that many of the signaling proteins and pathways thought to be activated in KRAS-mutant human lung adenocarcinomas based on studies with models systems are not activated, at least not at steady state levels as assayed by immunoblotting of tissue samples. Here, KRAS is linked to lung adenocarcinoma.